secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001193125-25-141087
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports 98% reduction in HAE attacks with lonvo-z over 3 years in Phase 1
--------------------------------------------------------------------------------

- Single dose led to mean 98% reduction in monthly HAE attack rate across all 10 patients.
- All patients attack-free and treatment-free for median 23 months at data cutoff.
- No treatment-emergent serious adverse events; infusional reactions mostly Grade 1, all resolved.
- Phase 3 HAELO trial screening completed ahead of schedule; >50% screened in U.S.
- Expects BLA submission in 2026 and U.S. launch in 2027, pending FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525141087/0001193125-25-141087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525141087/d82485d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-141087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer